Oncology Market Access Europe - Payer and Industry Perspectives

Oncology Market Access Europe - Payer and Industry Perspectives

Regular price $995.00 Sale

Published on Jul 03, 2014 - 75 pages

Oncology Market Access Europe - Payer and Industry Perspectives answers your questions:
  • What are payers looking for when making decisions regarding oncology reimbursement?
  • How are HTAs and other challenges affecting market access and what insight do payers offer?
  • How do payer decisions vary from market to market and what factors influence those decisions?
  • What will be the future role of real world data in payer decision-making?
  • What role do risk-sharing schemes, expanded access programmes and other pricing schemes play?
  • What factors should companies take into account when planning market access strategies?
  • Which innovations, such as PD-1 inhibitors, vaccines, personalised medicine and companion diagnostics show the most promise?
Oncology market access faces significant and mounting challenges as payers increase data requirements and financial austerity holds sway over decision-making. As pricing and reimbursement requirements become more stringent, issues of development cost, risk and slow market growth are at the forefront. In order to achieve market access success, companies need to adapt their approach and include health outcomes data to meet payer requirements.

Critical insight

Based on interviews and surveys with experts from the UK, Germany, Italy, France and Spain, FirstWord's Oncology Market Access Europe - Payer and Industry Perspectives lays out the current - and growing - challenges facing companies in getting drugs to the European market. Filled with compelling insight into the most pressing issues ranging from changing payer data requirements and financial austerity to the adoption of formalised HTA, the report offers critical strategies, knowledge and a roadmap to the future.

A report for the whole industry

The challenges for oncology market access are expected to increase and grow in the near future, making Oncology Market Access Europe - Payer and Industry Perspectives a must-read report not only for those working in market access, brand strategy, business development and licensing, but in biosimilars, payer relationships and drug innovation.

Key benefits, features and insights

Oncology market access is evolving and requires constant updates to keep abreast of changes. In this report, stakeholders will:
  • Gain insight into both the industry and payer perspectives, with particular reference to the increasing importance of robust clinical health outcomes data
  • Understand the key issues affecting access and how they vary between markets
  • Learn about key strategies for success, such as patient access schemes, price-volume agreements and price capping
  • Identify what effective strategies are used by which companies and why they work
  • Understand why the industry needs to adapt to an evolving and challenging landscape
  • Gain insight into how market access issues are driving decisions around R&D
Key Features
  • Insight into the innovative strategies being employed to gain market access
  • Overview of new drug approvals and oncology pipeline prospects such as cancer vaccines, niche indications and personalised medicine
  • Examination of the role of HTAs from both payer and industry perspectives
  • Key findings regarding the importance of early inclusion of market access considerations
Key Insights
  • How oncology market access varies from country to country and why
  • Complete overview of current oncology market access trends and challenges
  • The payer perspective on everything from transparency in information to the use of health outcomes data in decision making
  • How payers view the HTA process and its role in the short to medium term
Key experts interviewed
  • UK payer: Deputy Head of Medicines Management for a PCT with regional and local funding and budgetary decision making responsibility
  • German payer: Head of a national budgetary committee with national, regional and local funding and budgetary decision making responsibility
  • Italian payer: Pharmacist involved in purchasing of drugs and devices for hospital and with national, regional and local funding and budgetary decision making responsibility
  • Spanish payer: Professor of health economics and advisor to the Ministry of Health on pricing and reimbursement issues, with national, regional and local funding and budgetary decision making responsibility
  • French payer - Hospital pharmacist involved in buying medical products including drugs and medical devices for a group of nine hospitals with regional and local funding and budgetary decision making responsibility
  • Former oncology marketing manager, BMS
  • Oncology marketing manager, GSK
  • Oncology medical manager, GSK
  • Oncology market access, Pfizer

Table of Contents

1.Executive summary
1.2.Innovation has changed the course of the disease
1.3.The cost of treating cancer is expected to continue to rise
1.4.Innovative strategies for obtaining oncology market access are being employed
1.5.The challenges are expected to continue to grow - and with it, the importance of
a robust oncology market access strategy
2.Research objectives and methodology
3.1.Oncology market access is different for a variety of reasons
3.2.Despite the challenges, oncology market access is being achieved in many cases
4.Oncology market dynamics
4.1.Although a commercially significant sector, oncology has experienced a slowing
in growth in recent years
4.2.A number of new oncology drugs were approved in 2013
4.3.The current oncology pipeline is wide and varied - and offers some interesting prospects
4.4.The oncology market is dominated by several leading companies -
but there are many others with one or two key products
4.4.1.Roche - the market leader and oncology innovator
4.4.2.Novartis is re-establishing its oncology presence through acquisition
4.4.3.Pfizer is growing its portfolio through acquisition and targeted research
4.4.4.BMS is experiencing ongoing growth in oncology and has a promising pipeline
4.4.5.There are several smaller players with one or two key oncology drugs
4.5.Cancer vaccines, niche indications and personalised therapies are expected to
drive the oncology market in the near future
5.Market access in oncology
5.1.Obtaining market access for oncology drugs varies across different markets
5.2.What are the key challenges for oncology market access?
5.2.1.The payer perspective
5.2.2.The industry perspective
5.2.3.Different cancers present different challenges